{"id":390432,"date":"2019-05-06T00:00:00","date_gmt":"2019-05-06T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0046-2019-biopharma-atopic-dermatitis-atopic-eczema-treatment-algorithms-claims-data-analysis-pediatric-us-2019\/"},"modified":"2026-05-11T11:38:57","modified_gmt":"2026-05-11T11:38:57","slug":"algoim0046-2019-biopharma-atopic-dermatitis-atopic-eczema-treatment-algorithms-claims-data-analysis-pediatric-us-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0046-2019-biopharma-atopic-dermatitis-atopic-eczema-treatment-algorithms-claims-data-analysis-pediatric-us-2019\/","title":{"rendered":"Atopic Dermatitis\/Atopic Eczema | Treatment Algorithms: Claims Data Analysis | Pediatric | US | 2019"},"content":{"rendered":"<p>Atopic dermatitis (<abbr title=\"atopic dermatitis\">AD<\/abbr>) disproportionately affects children and adolescents, and its intermittent flares of itchy rash profoundly affect their quality of life. Most pediatric patients use prescribed topical corticosteroids for their symptoms; systemic immunomodulators are reserved for severe refractory cases. Pfizer\u2019s nonsteroidal topical agent Eucrisa and Sanofi\/Regeneron\u2019s Dupixent\u2014for which we expect\u00a0<abbr title=\"Food and Drug Administration\">FDA<\/abbr>\u00a0approval for adolescent\u00a0<abbr title=\"atopic dermatitis\">AD<\/abbr>\u00a0patients in 2019\u2014bring new options to distinct points in the\u00a0<abbr title=\"atopic dermatitis\">AD<\/abbr>\u00a0treatment algorithm. This claims data analysis assesses how these novel agents have begun to be integrated into patients\u2019 treatment, as well as how they compare with the therapeutic mainstays.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed pediatric\u00a0<abbr title=\"atopic dermatitis\">AD<\/abbr>\u00a0patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric\u00a0<abbr title=\"atopic dermatitis\">AD<\/abbr>\u00a0patients?<\/li>\n<li>How have Dupixent and Eucrisa been integrated into the treatment algorithm for pediatric\u00a0<abbr title=\"atopic dermatitis\">AD<\/abbr>, and what are their sources of business?<\/li>\n<li>What percentage of pediatric\u00a0<abbr title=\"atopic dermatitis\">AD<\/abbr>\u00a0patients receive drug therapy within one year of diagnosis, and how quickly do they receive it? What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n<li>What percentage of pediatric\u00a0<abbr title=\"atopic dermatitis\">AD<\/abbr>\u00a0patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations? What are the product-level compliance and persistency rates among drug-treated pediatric\u00a0<abbr title=\"atopic dermatitis\">AD<\/abbr>\u00a0patients?<\/li>\n<\/ul>\n<p><strong>GEOGRAPHIES<\/strong><\/p>\n<p>United States<\/p>\n<p><strong>KEY DRUGS COVERED<\/strong><\/p>\n<p>Dupixent, Eucrisa, Protopic, Elidel, cyclosporine, methotrexate, azathioprine, mycophenolate mofetil, topical corticosteroids<\/p>\n<p><strong>KEY ANALYSIS PROVIDED<\/strong><\/p>\n<p>Brand\/therapy usage across a longitudinal patient sample.<\/p>\n<p>Newly diagnosed patient analysis.<\/p>\n<p>Treatment initiation and progression.<\/p>\n<p>Line of therapy analysis.<\/p>\n<p>Combination therapy analysis.<\/p>\n<p>Source of business for recently treated patients.<\/p>\n<p>Persistency and compliance analysis.<\/p>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>Treatment Algorithms: Claims Data Analysis\u00a0<\/em>provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.<\/p>\n","protected":false},"template":"","class_list":["post-390432","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390432","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390432\/revisions"}],"predecessor-version":[{"id":393557,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390432\/revisions\/393557"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390432"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}